<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00345176</url>
  </required_header>
  <id_info>
    <org_study_id>NEI-120</org_study_id>
    <secondary_id>N01-EY-5-0007</secondary_id>
    <secondary_id>HHS-N-260-2005-00007-C</secondary_id>
    <secondary_id>CC-070025</secondary_id>
    <secondary_id>07-EI-0025</secondary_id>
    <nct_id>NCT00345176</nct_id>
    <nct_alias>NCT00409513</nct_alias>
  </id_info>
  <brief_title>Age-Related Eye Disease Study 2 (AREDS2)</brief_title>
  <acronym>AREDS2</acronym>
  <official_title>Age-Related Eye Disease Study 2 (AREDS2): A Multi-center, Randomized Trial of Lutein, Zeaxanthin and Omega-3 Long-Chain Polyunsaturated Fatty Acids (Docosahexaenoic Acid [DHA] and Eicosapentaenoic Acid [EPA]) in Age-Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Office of Dietary Supplements (ODS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Eye Institute (NEI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oral supplementation with the Age-Related Eye Disease Study (AREDS) formulation (antioxidant
      vitamins C and E, beta carotene, and zinc) has been shown to reduce the risk of progression
      to advanced age-related macular degeneration (AMD). Observational data suggest that increased
      dietary intake of lutein + zeaxanthin (carotenoids), omega-3 long-chain polyunsaturated fatty
      acids (docosahexaenoic acid [DHA] + eicosapentaenoic acid [EPA]), or both might further
      reduce this risk. AREDS2 was designed to test whether adding lutein + zeaxanthin, DHA + EPA,
      or lutein + zeaxanthin and DHA + EPA to the AREDS formulation might further reduce the risk
      of progression to advanced AMD. A secondary goal was to test the effects of eliminating beta
      carotene and reducing zinc dose in the AREDS formulation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AREDS2 was a randomized, double-masked, placebo-controlled, 2x2 factorial trial evaluating
      the risks and benefits of adding lutein (10 mg) + zeaxanthin (2 mg), DHA (350 mg) + EPA (650
      mg), or both to the AREDS formulation, which consisted of vitamins C (500 mg), vitamin E (400
      international units), beta carotene (15 mg), zinc (80 mg as zinc oxide), and copper (2 mg as
      cupric oxide) for the treatment of progression to advanced AMD. The study enrolled 4,203
      participants aged 50 to 85 years, with sufficiently clear ocular media to allow accurate
      assessment of AMD from fundus photographs. Subjects were enrolled on the basis of the AREDS
      Simplified Severity Scale for defining risk categories for development of advanced
      age-related macular degeneration. All participants were offered additional treatment with the
      original AREDS formulation (now considered standard of care) and 3 variations of this
      formula. These are: (1) no beta-carotene; (2) lower amount of zinc (25 mg); and (3) no
      beta-carotene and lower amount of zinc (25 mg). Eligible participants were followed for a
      minimum of five years.

      Multiple ancillary studies were conducted using the parent study (AREDS2) data to explore:

        1. Effects of oral supplementation of omega-3 fatty acids, lutein/zeaxanthin, zinc, and
           beta-carotene on cognitive function

             1. Outcome is measured with a battery of tests administered over the telephone at
                baseline, and at years 2 and 4 of the study.

             2. Primary outcome is the change in the composite score for the results of the
                cognitive function testing from baseline over time.

        2. Effects of oral supplementation of omega-3 fatty acids, lutein/zeaxanthin on
           cardiovascular disease

           a. Primary measure of cardiovascular morbidity and mortality

        3. Effects of oral supplementation of omega-3 fatty acids, lutein/zeaxanthin on the
           peripheral retina

           a. Primary outcome is the development of peripheral drusen, geographic atrophy,
           reticular pigmentary changes, and pseudoreticular drusen.

        4. Association of genotype polymorphisms with age-related macular degeneration and cataract

           a. Whole genome sequencing will be completed. Evaluation of association genetic
           associations with disease will be conducted using AREDS controls.

        5. Association of genotype polymorphisms with progression of age-related macular
           degeneration

           a. Whole genome sequencing is conducted. Progression from early to late and severe
           stages of AMD will be examined with the genotype data to evaluate the risks of
           progression associated with the genotype polymorphisms.

        6. Association of genotype polymorphisms with dietary intake a. Whole genome sequencing is
           conducted. Progression from early to late and severe stages of AMD will be examined
           regarding potential interaction of the dietary intake with the genotype data to evaluate
           the risks of progression.

        7. Association of genotype polymorphisms with AREDS2 supplements a. Interaction of genetic
           polymorphisms with AREDS2 supplements for progression to late AMD will be evaluated
           using the data from the whole genome sequencing project.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Development of Advanced AMD in People at Moderate to High Risk for Progression.</measure>
    <time_frame>5 years of follow-up</time_frame>
    <description>Defined as central geographic atrophy or retinal features of choroidal neovascularization detected on central grading of the stereoscopic fundus photographs or a history of treatment for advanced AMD after study enrollment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression to Moderate Vision Loss</measure>
    <time_frame>5 years of follow-up</time_frame>
    <description>Loss defined as &gt;/= 3 lines of letters from baseline or treatment for choroidal neovascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>5 years of follow-up</time_frame>
    <description>Safety outcomes included serious adverse events and mortality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression to Cataract Surgery</measure>
    <time_frame>5 years of follow-up</time_frame>
    <description>The study examined the effects of lutein/zeaxanthin on progression to cataract surgery with data collected during regular telephone contacts and the annual study visits.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incident Cardiovascular Disease</measure>
    <time_frame>5 years of follow-up</time_frame>
    <description>Effects of oral supplementation of omega-3 fatty acids, lutein/zeaxanthin on cardiovascular disease</description>
  </other_outcome>
  <other_outcome>
    <measure>Cognition as Measured by a Telephone Battery</measure>
    <time_frame>5 years of follow-up</time_frame>
    <description>Effects of oral supplementation of omega-3 fatty acids, lutein/zeaxanthin, zinc, and beta-carotene on cognitive function</description>
  </other_outcome>
  <other_outcome>
    <measure>Prevalence of Peripheral Changes as Measured Using OPTOS Imaging</measure>
    <time_frame>5 years of follow-up</time_frame>
    <description>Effects of oral supplementation of omega-3 fatty acids, lutein/zeaxanthin on the peripheral retina</description>
  </other_outcome>
  <other_outcome>
    <measure>Genetics for the Association of AMD and Cataract</measure>
    <time_frame>5 years of follow-up</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Genetics for the Progression of AMD and Cataract</measure>
    <time_frame>5 years of follow-up</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">4203</enrollment>
  <condition>Age-related Macular Degeneration</condition>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Lutein/Zeaxanthin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>lutein (10mg)/zeaxanthin (2 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DHA/EPA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DHA (350 mg)/EPA (650 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lutein/Zeaxanthin + DHA/EPA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>lutein (10 mg)/zeaxanthin (2 mg) + DHA (350 mg)/EPA (650 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Considered control because all participants received the AREDS formulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lutein/zeaxanthin</intervention_name>
    <description>10 mg lutein and 2 mg zeaxanthin (1 tablet) Placebo-DHA/EPA (2 soft-gel capsules)</description>
    <arm_group_label>Lutein/Zeaxanthin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>DHA/EPA</intervention_name>
    <description>Placebo-lutein/zeaxanthin (1 tablet) 350 mg DHA and 650 mg EPA (2 soft-gel capsules)</description>
    <arm_group_label>DHA/EPA</arm_group_label>
    <other_name>docosahexaenoic acid; eicosapentaenoic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lutein/zeaxanthin and DHA/EPA</intervention_name>
    <description>10 mg lutein and 2 mg zeaxanthin (1 tablet) 350 mg DHA and 650 mg EPA (2 soft-gel capsules)</description>
    <arm_group_label>Lutein/Zeaxanthin + DHA/EPA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women between the ages of 50 and 85 years

          -  Macular status ranges from large drusen in both eyes or large drusen in one eye and
             advanced AMD (neovascular AMD or geographic atrophy) in the fellow eye

        Exclusion Criteria:

          -  Ocular media not clear enough to allow good fundus photography
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emily Y Chew, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Eye Institute, National Institutes of Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Paul SanGiovanni, Sc.D.</last_name>
    <role>Study Director</role>
    <affiliation>National Eye Institute, National Institutes of Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jones Eye Institute - UAMS</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina-Vitreous Associates Medical Group</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shiley Eye Center - UCSD</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda University</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doheny Eye Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jules Stein Eye Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Northern California Health Care System</name>
      <address>
        <city>Martinez</city>
        <state>California</state>
        <zip>94553</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern California Desert Retina Consultants, MC</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Coast Retina Medical Group, Inc</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Eye Associates</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Retina Associates</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eldorado Retina Associates, PC</name>
      <address>
        <city>Louisville</city>
        <state>Colorado</state>
        <zip>80027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University Eye Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Group of Florida</name>
      <address>
        <city>Ft. Lauderdale</city>
        <state>Florida</state>
        <zip>33334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bascom Palmer Eye Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarasota Retina Institute</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Retina and Macular Disease</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33880</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Eye Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Retina, PC</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Illinois</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NorthShore University HealthSystems</name>
      <address>
        <city>Glenview</city>
        <state>Illinois</state>
        <zip>60026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ingalls Memorial Hospital</name>
      <address>
        <city>Harvey</city>
        <state>Illinois</state>
        <zip>60426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Associates of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paducah Retinal Center</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <zip>42001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elman Retina Group</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilmer Eye Institute, Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Eye Institute</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Retina Group of Washington</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts Eye and Ear Infirmary</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Consultants of Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kresge Eye Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System - Eye Care Services</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vision Research Foundation</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vision Research Foundation</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vision Research Foundation</name>
      <address>
        <city>Traverse City</city>
        <state>Michigan</state>
        <zip>49686</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Care - Mason Eye Institute</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Foundation of Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid-America Retina Consultants, PA</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Retina Institute</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Delaware Valley Retina Associates</name>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>08648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMDNJ</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Consultants of Long Island</name>
      <address>
        <city>Lynbrook</city>
        <state>New York</state>
        <zip>11563</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Eye and Ear Infirmary</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manhattan Eye, Ear and Throat Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Eye Institute</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Consultants, PLLC</name>
      <address>
        <city>Slingerlands</city>
        <state>New York</state>
        <zip>12159</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Research Foundation of SUNY/Stony Brook</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Carolina Retinal Associates</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Department of Ophthalmology</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlotte Eye Ear Nose and Throat Associates</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Eye Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Associates of Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Associates of Cleveland</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Associates of Cleveland</name>
      <address>
        <city>Youngstown</city>
        <state>Ohio</state>
        <zip>44505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dean McGee Eye Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Devers Eye Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Northwest, PC</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennsylvania Retina Specialists, PC</name>
      <address>
        <city>Camp Hill</city>
        <state>Pennsylvania</state>
        <zip>17011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State M.S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scheie Eye Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wills Eye Hospital/Mid Atlantic Retina</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Vitreous Consultants</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Retina Center</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Retina Center</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Retina Associates, PC</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38163</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Eye Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Retina Associates</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Retina Associates</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Retina Associates</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79424</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott and White Memorial Hospital</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Moran Eye Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fletcher Allen Health Care</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Retina Group of Washington</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Center Northwest</name>
      <address>
        <city>Silverdale</city>
        <state>Washington</state>
        <zip>98383</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nei.nih.gov/areds2/</url>
    <description>NEI Website: Age-Related Eye Disease Study 2</description>
  </link>
  <link>
    <url>http://www.areds2.org</url>
    <description>AREDS2 Website</description>
  </link>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2006</study_first_submitted>
  <study_first_submitted_qc>June 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2006</study_first_posted>
  <results_first_submitted>November 1, 2013</results_first_submitted>
  <results_first_submitted_qc>November 1, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 24, 2013</results_first_posted>
  <last_update_submitted>April 13, 2015</last_update_submitted>
  <last_update_submitted_qc>April 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>age-related macular degeneration</keyword>
  <keyword>AMD</keyword>
  <keyword>lutein</keyword>
  <keyword>zeaxanthin</keyword>
  <keyword>docosahexaenoic acid</keyword>
  <keyword>eicosapentaenoic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between October 2006 and September 2008 a total of 4,203 participants aged 50 - 85 years were randomized at 82 clinical sites.</recruitment_details>
      <pre_assignment_details>Prior to randomization, participants had to complete the Qualification phase. They could only be randomized if they took at least 75% of the run-in medication.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo/Control</title>
          <description>Considered control because all participants received the AREDS formulation</description>
        </group>
        <group group_id="P2">
          <title>Lutein/Zeaxanthin</title>
          <description>lutein (10mg)/zeaxanthin (2 mg)</description>
        </group>
        <group group_id="P3">
          <title>DHA/EPA</title>
          <description>DHA (350 mg)/EPA (650 mg)</description>
        </group>
        <group group_id="P4">
          <title>Lutein/Zeaxanthin + DHA/EPA</title>
          <description>lutein (10 mg)/zeaxanthin (2 mg) + DHA (350 mg)/EPA (650 mg)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1012"/>
                <participants group_id="P2" count="1044"/>
                <participants group_id="P3" count="1068"/>
                <participants group_id="P4" count="1079"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1007"/>
                <participants group_id="P2" count="1038"/>
                <participants group_id="P3" count="1062"/>
                <participants group_id="P4" count="1069"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo/Control</title>
          <description>Considered control because all participants received the AREDS formulation</description>
        </group>
        <group group_id="B2">
          <title>Lutein/Zeaxanthin</title>
          <description>lutein (10mg)/zeaxanthin (2 mg)</description>
        </group>
        <group group_id="B3">
          <title>DHA/EPA</title>
          <description>DHA (350 mg)/EPA (650 mg)</description>
        </group>
        <group group_id="B4">
          <title>Lutein/Zeaxanthin + DHA/EPA</title>
          <description>lutein (10 mg)/zeaxanthin (2 mg) + DHA (350 mg)/EPA (650 mg)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1012"/>
            <count group_id="B2" value="1044"/>
            <count group_id="B3" value="1068"/>
            <count group_id="B4" value="1079"/>
            <count group_id="B5" value="4203"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74" lower_limit="68" upper_limit="79"/>
                    <measurement group_id="B2" value="74" lower_limit="68" upper_limit="79"/>
                    <measurement group_id="B3" value="74" lower_limit="68" upper_limit="79"/>
                    <measurement group_id="B4" value="75" lower_limit="68" upper_limit="79"/>
                    <measurement group_id="B5" value="74" lower_limit="68" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="548"/>
                    <measurement group_id="B2" value="596"/>
                    <measurement group_id="B3" value="603"/>
                    <measurement group_id="B4" value="641"/>
                    <measurement group_id="B5" value="2388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="464"/>
                    <measurement group_id="B2" value="448"/>
                    <measurement group_id="B3" value="465"/>
                    <measurement group_id="B4" value="438"/>
                    <measurement group_id="B5" value="1815"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Development of Advanced AMD in People at Moderate to High Risk for Progression.</title>
        <description>Defined as central geographic atrophy or retinal features of choroidal neovascularization detected on central grading of the stereoscopic fundus photographs or a history of treatment for advanced AMD after study enrollment.</description>
        <time_frame>5 years of follow-up</time_frame>
        <population>Intention to Treat. Participants lost to follow-up during the course of the study were censored at the time of last contact.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Control</title>
            <description>Considered control because all participants received the AREDS formulation</description>
          </group>
          <group group_id="O2">
            <title>Lutein/Zeaxanthin</title>
            <description>lutein (10mg)/zeaxanthin (2 mg)</description>
          </group>
          <group group_id="O3">
            <title>DHA/EPA</title>
            <description>DHA (350 mg)/EPA (650 mg)</description>
          </group>
          <group group_id="O4">
            <title>Lutein/Zeaxanthin + DHA/EPA</title>
            <description>lutein (10 mg)/zeaxanthin (2 mg) + DHA (350 mg)/EPA (650 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Development of Advanced AMD in People at Moderate to High Risk for Progression.</title>
          <description>Defined as central geographic atrophy or retinal features of choroidal neovascularization detected on central grading of the stereoscopic fundus photographs or a history of treatment for advanced AMD after study enrollment.</description>
          <population>Intention to Treat. Participants lost to follow-up during the course of the study were censored at the time of last contact.</population>
          <units>Eyes</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1007"/>
                <count group_id="O2" value="1038"/>
                <count group_id="O3" value="1062"/>
                <count group_id="O4" value="1069"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1691"/>
                <count group_id="O2" value="1709"/>
                <count group_id="O3" value="1749"/>
                <count group_id="O4" value="1742"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="493"/>
                    <measurement group_id="O2" value="468"/>
                    <measurement group_id="O3" value="507"/>
                    <measurement group_id="O4" value="472"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Each of the 3 active arms was compared to the placebo/control arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.013</p_value>
            <p_value_desc>Adjusted for 3 treatment versus placebo comparisons and interim analyses</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>Adjusted for baseline AMD status</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.90</param_value>
            <ci_percent>98.7</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
            <estimate_desc>The reference group is placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.013</p_value>
            <p_value_desc>Adjusted for multiple comparisons</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.97</param_value>
            <ci_percent>98.7</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.013</p_value>
            <method>Regression, Cox</method>
            <method_desc>Adjusted for multiple comparisons</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.89</param_value>
            <ci_percent>98.7</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression to Moderate Vision Loss</title>
        <description>Loss defined as &gt;/= 3 lines of letters from baseline or treatment for choroidal neovascularization</description>
        <time_frame>5 years of follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Control</title>
            <description>Considered control because all participants received the AREDS formulation</description>
          </group>
          <group group_id="O2">
            <title>Lutein/Zeaxanthin</title>
            <description>lutein (10mg)/zeaxanthin (2 mg)</description>
          </group>
          <group group_id="O3">
            <title>DHA/EPA</title>
            <description>DHA (350 mg)/EPA (650 mg)</description>
          </group>
          <group group_id="O4">
            <title>Lutein/Zeaxanthin + DHA/EPA</title>
            <description>lutein (10 mg)/zeaxanthin (2 mg) + DHA (350 mg)/EPA (650 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Progression to Moderate Vision Loss</title>
          <description>Loss defined as &gt;/= 3 lines of letters from baseline or treatment for choroidal neovascularization</description>
          <units>Eyes</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1007"/>
                <count group_id="O2" value="1038"/>
                <count group_id="O3" value="1062"/>
                <count group_id="O4" value="1069"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1630"/>
                <count group_id="O2" value="1660"/>
                <count group_id="O3" value="1694"/>
                <count group_id="O4" value="1672"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="515"/>
                    <measurement group_id="O2" value="509"/>
                    <measurement group_id="O3" value="519"/>
                    <measurement group_id="O4" value="506"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>Safety outcomes included serious adverse events and mortality.</description>
        <time_frame>5 years of follow-up</time_frame>
        <population>Number of deaths in 5 years</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Control</title>
            <description>Considered control because all participants received the AREDS formulation</description>
          </group>
          <group group_id="O2">
            <title>Lutein/Zeaxanthin</title>
            <description>lutein (10mg)/zeaxanthin (2 mg)</description>
          </group>
          <group group_id="O3">
            <title>DHA/EPA</title>
            <description>DHA (350 mg)/EPA (650 mg)</description>
          </group>
          <group group_id="O4">
            <title>Lutein/Zeaxanthin + DHA/EPA</title>
            <description>lutein (10 mg)/zeaxanthin (2 mg) + DHA (350 mg)/EPA (650 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Safety outcomes included serious adverse events and mortality.</description>
          <population>Number of deaths in 5 years</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1012"/>
                <count group_id="O2" value="1044"/>
                <count group_id="O3" value="1068"/>
                <count group_id="O4" value="1079"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mortality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="87"/>
                    <measurement group_id="O3" value="96"/>
                    <measurement group_id="O4" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="479"/>
                    <measurement group_id="O2" value="484"/>
                    <measurement group_id="O3" value="505"/>
                    <measurement group_id="O4" value="519"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Lutein/Zeaxantin versus Control for mortality</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of DHA/EPA versus Placebo for mortality</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison of Lutein/Zeaxanthin + DHA/EPA versus Placebo for Mortality</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.65</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression to Cataract Surgery</title>
        <description>The study examined the effects of lutein/zeaxanthin on progression to cataract surgery with data collected during regular telephone contacts and the annual study visits.</description>
        <time_frame>5 years of follow-up</time_frame>
        <population>Includes participants who were phakic in at least 1 eye at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>No Lutein/Zeaxanthin</title>
            <description>Lutein main effect - includes participants who did not receive Lutein/Zeaxanthin</description>
          </group>
          <group group_id="O2">
            <title>Lutein/Zeaxanthin</title>
            <description>Lutein main effect - includes all participants who received Lutein/Zeaxanthin</description>
          </group>
        </group_list>
        <measure>
          <title>Progression to Cataract Surgery</title>
          <description>The study examined the effects of lutein/zeaxanthin on progression to cataract surgery with data collected during regular telephone contacts and the annual study visits.</description>
          <population>Includes participants who were phakic in at least 1 eye at baseline</population>
          <units>Eyes</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1577"/>
                <count group_id="O2" value="1578"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3022"/>
                <count group_id="O2" value="3005"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="708"/>
                    <measurement group_id="O2" value="681"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Incident Cardiovascular Disease</title>
        <description>Effects of oral supplementation of omega-3 fatty acids, lutein/zeaxanthin on cardiovascular disease</description>
        <time_frame>5 years of follow-up</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cognition as Measured by a Telephone Battery</title>
        <description>Effects of oral supplementation of omega-3 fatty acids, lutein/zeaxanthin, zinc, and beta-carotene on cognitive function</description>
        <time_frame>5 years of follow-up</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Prevalence of Peripheral Changes as Measured Using OPTOS Imaging</title>
        <description>Effects of oral supplementation of omega-3 fatty acids, lutein/zeaxanthin on the peripheral retina</description>
        <time_frame>5 years of follow-up</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Genetics for the Association of AMD and Cataract</title>
        <time_frame>5 years of follow-up</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Genetics for the Progression of AMD and Cataract</title>
        <time_frame>5 years of follow-up</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 years</time_frame>
      <desc>Adverse events reported by System Organ Class</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo/Control</title>
          <description>Considered control because all participants received the AREDS formulation</description>
        </group>
        <group group_id="E2">
          <title>Lutein/Zeaxanthin</title>
          <description>lutein (10mg)/zeaxanthin (2 mg)</description>
        </group>
        <group group_id="E3">
          <title>DHA/EPA</title>
          <description>DHA (350 mg)/EPA (650 mg)</description>
        </group>
        <group group_id="E4">
          <title>Lutein/Zeaxanthin + DHA/EPA</title>
          <description>lutein (10 mg)/zeaxanthin (2 mg) + DHA (350 mg)/EPA (650 mg)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="479" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="484" subjects_at_risk="1044"/>
                <counts group_id="E3" subjects_affected="505" subjects_at_risk="1068"/>
                <counts group_id="E4" subjects_affected="519" subjects_at_risk="1079"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and lymphatic system disorders</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="1012"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="1044"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="1068"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="1079"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Disorders</sub_title>
                <counts group_id="E1" events="122" subjects_affected="96" subjects_at_risk="1012"/>
                <counts group_id="E2" events="138" subjects_affected="110" subjects_at_risk="1044"/>
                <counts group_id="E3" events="144" subjects_affected="119" subjects_at_risk="1068"/>
                <counts group_id="E4" events="133" subjects_affected="103" subjects_at_risk="1079"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital, familian and genetic disorders</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1012"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1044"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1068"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1079"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear and labyrinth disorders</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1012"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1044"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="1068"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1079"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1012"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1044"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="1068"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1079"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye disorders</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1012"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="1044"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="1068"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1079"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <counts group_id="E1" events="101" subjects_affected="76" subjects_at_risk="1012"/>
                <counts group_id="E2" events="81" subjects_affected="69" subjects_at_risk="1044"/>
                <counts group_id="E3" events="72" subjects_affected="58" subjects_at_risk="1068"/>
                <counts group_id="E4" events="71" subjects_affected="61" subjects_at_risk="1079"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions</sub_title>
                <counts group_id="E1" events="60" subjects_affected="54" subjects_at_risk="1012"/>
                <counts group_id="E2" events="54" subjects_affected="50" subjects_at_risk="1044"/>
                <counts group_id="E3" events="58" subjects_affected="51" subjects_at_risk="1068"/>
                <counts group_id="E4" events="50" subjects_affected="46" subjects_at_risk="1079"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary disorders</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="1012"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="1044"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="1068"/>
                <counts group_id="E4" events="18" subjects_affected="17" subjects_at_risk="1079"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immune system disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1012"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1044"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="1068"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="1079"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <counts group_id="E1" events="109" subjects_affected="90" subjects_at_risk="1012"/>
                <counts group_id="E2" events="139" subjects_affected="102" subjects_at_risk="1044"/>
                <counts group_id="E3" events="144" subjects_affected="103" subjects_at_risk="1068"/>
                <counts group_id="E4" events="127" subjects_affected="99" subjects_at_risk="1079"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning and procedural complications</sub_title>
                <counts group_id="E1" events="90" subjects_affected="76" subjects_at_risk="1012"/>
                <counts group_id="E2" events="72" subjects_affected="62" subjects_at_risk="1044"/>
                <counts group_id="E3" events="90" subjects_affected="74" subjects_at_risk="1068"/>
                <counts group_id="E4" events="84" subjects_affected="66" subjects_at_risk="1079"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="1012"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="1044"/>
                <counts group_id="E3" events="15" subjects_affected="13" subjects_at_risk="1068"/>
                <counts group_id="E4" events="12" subjects_affected="12" subjects_at_risk="1079"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and nutrition disorders</sub_title>
                <counts group_id="E1" events="22" subjects_affected="21" subjects_at_risk="1012"/>
                <counts group_id="E2" events="18" subjects_affected="16" subjects_at_risk="1044"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="1068"/>
                <counts group_id="E4" events="25" subjects_affected="23" subjects_at_risk="1079"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders</sub_title>
                <counts group_id="E1" events="77" subjects_affected="66" subjects_at_risk="1012"/>
                <counts group_id="E2" events="91" subjects_affected="74" subjects_at_risk="1044"/>
                <counts group_id="E3" events="85" subjects_affected="71" subjects_at_risk="1068"/>
                <counts group_id="E4" events="101" subjects_affected="85" subjects_at_risk="1079"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</sub_title>
                <counts group_id="E1" events="103" subjects_affected="80" subjects_at_risk="1012"/>
                <counts group_id="E2" events="111" subjects_affected="88" subjects_at_risk="1044"/>
                <counts group_id="E3" events="100" subjects_affected="83" subjects_at_risk="1068"/>
                <counts group_id="E4" events="112" subjects_affected="92" subjects_at_risk="1079"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <counts group_id="E1" events="73" subjects_affected="66" subjects_at_risk="1012"/>
                <counts group_id="E2" events="93" subjects_affected="74" subjects_at_risk="1044"/>
                <counts group_id="E3" events="87" subjects_affected="72" subjects_at_risk="1068"/>
                <counts group_id="E4" events="86" subjects_affected="73" subjects_at_risk="1079"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric disorders</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1012"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1044"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="1068"/>
                <counts group_id="E4" events="11" subjects_affected="9" subjects_at_risk="1079"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="1012"/>
                <counts group_id="E2" events="26" subjects_affected="25" subjects_at_risk="1044"/>
                <counts group_id="E3" events="25" subjects_affected="24" subjects_at_risk="1068"/>
                <counts group_id="E4" events="29" subjects_affected="25" subjects_at_risk="1079"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Reproductive system and breast disorders</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="1012"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="1044"/>
                <counts group_id="E3" events="13" subjects_affected="12" subjects_at_risk="1068"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="1079"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respioratory, thoracic and mediastinal disorders</sub_title>
                <counts group_id="E1" events="59" subjects_affected="44" subjects_at_risk="1012"/>
                <counts group_id="E2" events="52" subjects_affected="43" subjects_at_risk="1044"/>
                <counts group_id="E3" events="50" subjects_affected="37" subjects_at_risk="1068"/>
                <counts group_id="E4" events="51" subjects_affected="46" subjects_at_risk="1079"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1012"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="1044"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="1068"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="1079"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical procedures</sub_title>
                <counts group_id="E1" events="32" subjects_affected="32" subjects_at_risk="1012"/>
                <counts group_id="E2" events="31" subjects_affected="29" subjects_at_risk="1044"/>
                <counts group_id="E3" events="30" subjects_affected="27" subjects_at_risk="1068"/>
                <counts group_id="E4" events="32" subjects_affected="32" subjects_at_risk="1079"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular disorders</sub_title>
                <counts group_id="E1" events="45" subjects_affected="41" subjects_at_risk="1012"/>
                <counts group_id="E2" events="42" subjects_affected="40" subjects_at_risk="1044"/>
                <counts group_id="E3" events="45" subjects_affected="42" subjects_at_risk="1068"/>
                <counts group_id="E4" events="46" subjects_affected="42" subjects_at_risk="1079"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="717" subjects_at_risk="1012"/>
                <counts group_id="E2" subjects_affected="791" subjects_at_risk="1044"/>
                <counts group_id="E3" subjects_affected="759" subjects_at_risk="1068"/>
                <counts group_id="E4" subjects_affected="791" subjects_at_risk="1079"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="62" subjects_affected="55" subjects_at_risk="1012"/>
                <counts group_id="E2" events="40" subjects_affected="39" subjects_at_risk="1044"/>
                <counts group_id="E3" events="70" subjects_affected="64" subjects_at_risk="1068"/>
                <counts group_id="E4" events="70" subjects_affected="62" subjects_at_risk="1079"/>
              </event>
              <event>
                <sub_title>Eye disorder</sub_title>
                <counts group_id="E1" events="100" subjects_affected="67" subjects_at_risk="1012"/>
                <counts group_id="E2" events="96" subjects_affected="67" subjects_at_risk="1044"/>
                <counts group_id="E3" events="98" subjects_affected="62" subjects_at_risk="1068"/>
                <counts group_id="E4" events="152" subjects_affected="82" subjects_at_risk="1079"/>
              </event>
              <event>
                <sub_title>Visual disturbance</sub_title>
                <counts group_id="E1" events="118" subjects_affected="88" subjects_at_risk="1012"/>
                <counts group_id="E2" events="139" subjects_affected="110" subjects_at_risk="1044"/>
                <counts group_id="E3" events="116" subjects_affected="84" subjects_at_risk="1068"/>
                <counts group_id="E4" events="119" subjects_affected="88" subjects_at_risk="1079"/>
              </event>
              <event>
                <sub_title>Vitreous disorder</sub_title>
                <counts group_id="E1" events="208" subjects_affected="133" subjects_at_risk="1012"/>
                <counts group_id="E2" events="213" subjects_affected="154" subjects_at_risk="1044"/>
                <counts group_id="E3" events="228" subjects_affected="165" subjects_at_risk="1068"/>
                <counts group_id="E4" events="208" subjects_affected="162" subjects_at_risk="1079"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Change in bowel habit</sub_title>
                <counts group_id="E1" events="69" subjects_affected="57" subjects_at_risk="1012"/>
                <counts group_id="E2" events="77" subjects_affected="67" subjects_at_risk="1044"/>
                <counts group_id="E3" events="58" subjects_affected="48" subjects_at_risk="1068"/>
                <counts group_id="E4" events="60" subjects_affected="57" subjects_at_risk="1079"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="72" subjects_affected="62" subjects_at_risk="1012"/>
                <counts group_id="E2" events="83" subjects_affected="69" subjects_at_risk="1044"/>
                <counts group_id="E3" events="80" subjects_affected="57" subjects_at_risk="1068"/>
                <counts group_id="E4" events="66" subjects_affected="56" subjects_at_risk="1079"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="175" subjects_affected="139" subjects_at_risk="1012"/>
                <counts group_id="E2" events="190" subjects_affected="150" subjects_at_risk="1044"/>
                <counts group_id="E3" events="179" subjects_affected="139" subjects_at_risk="1068"/>
                <counts group_id="E4" events="173" subjects_affected="138" subjects_at_risk="1079"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="82" subjects_affected="57" subjects_at_risk="1012"/>
                <counts group_id="E2" events="103" subjects_affected="75" subjects_at_risk="1044"/>
                <counts group_id="E3" events="108" subjects_affected="71" subjects_at_risk="1068"/>
                <counts group_id="E4" events="96" subjects_affected="73" subjects_at_risk="1079"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="66" subjects_affected="59" subjects_at_risk="1012"/>
                <counts group_id="E2" events="62" subjects_affected="60" subjects_at_risk="1044"/>
                <counts group_id="E3" events="72" subjects_affected="69" subjects_at_risk="1068"/>
                <counts group_id="E4" events="73" subjects_affected="73" subjects_at_risk="1079"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Traci Clemons, PhD</name_or_title>
      <organization>The EMMES Corporation</organization>
      <phone>301-251-1161 ext 212</phone>
      <email>tclemons@emmes.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

